-    Overview
-    STAT3 P705

Cancer Signaling

Exosomes are small vesicles produced by and shed from cancer cells in highly elevated amounts to carry out, or influence, almost all pathogenic actions of tumor cells:

The field of exosome research has produced abundant literature on all these, and exosomes are increasingly recognized as central mediator in cancer formation, progression, metastasis, metabolic dysregulation, as well as its ability to resist both chemotherapies and checkpoint inhibitors.

Inhibition of exosomes appears to offer a promising and highly novel intervention in cancer. Aluda has proven that its vimentin binding small molecules, including ALD-R491, can intervene in the biogenesis and release of exosomes in tumor cells, with no negative impacts on normal cell biology. Data includes extensive in vitro and in vivo evidence with both negative effects on tumors, and positive effects on normal cells.

Aluda’s Exosome Release Inhibitors (ExoRIs) provide the first effective tools to refine clinical translation of this important field to novel anti-cancer agents that are anti-metastatic, anti-TME, and prevent systemic dysregulation of cancer.


This document was printed from http://www.aludapharm.com/pipeline/cancer-signaling.html